TriSalus Life Sciences Inc
NASDAQ:TLSI
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.62
10.25
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
TriSalus Life Sciences Inc
Total Liabilities & Equity
TriSalus Life Sciences Inc
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
T
|
TriSalus Life Sciences Inc
NASDAQ:TLSI
|
Total Liabilities & Equity
$25.7m
|
CAGR 3-Years
-53%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
N
|
Nextdoor Holdings Inc
NYSE:KIND
|
Total Liabilities & Equity
$654.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Flame Acquisition Corp
NYSE:SOC
|
Total Liabilities & Equity
$63.9m
|
CAGR 3-Years
495%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Core Scientific Inc
NASDAQ:CORZ
|
Total Liabilities & Equity
$712.2m
|
CAGR 3-Years
47%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Symbotic Inc
NASDAQ:SYM
|
Total Liabilities & Equity
$1.6B
|
CAGR 3-Years
79%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Rumble Inc
NASDAQ:RUM
|
Total Liabilities & Equity
$295.7m
|
CAGR 3-Years
378%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
TriSalus Life Sciences Inc
Glance View
TriSalus Life Sciences Inc is a US-based company operating in industry. The company is headquartered in Westminster, Colorado. The company went IPO on 2020-12-18. TriSalus Life Sciences, Inc. is an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors. The Company’s platform includes devices that utilize a drug delivery technology and a clinical-stage investigational immunotherapy. The Company’s two FDA-cleared devices use its Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. SD-101, the Company’s investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment. Patient data generated during Pressure-Enabled Regional Immuno-Oncology (PERIO) clinical trials support the hypothesis that SD-101 delivered through PEDD may has favorable immune effects on the liver and systemically.
See Also
What is TriSalus Life Sciences Inc's Total Liabilities & Equity?
Total Liabilities & Equity
25.7m
USD
Based on the financial report for Dec 31, 2023, TriSalus Life Sciences Inc's Total Liabilities & Equity amounts to 25.7m USD.
What is TriSalus Life Sciences Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 3Y
-53%
Over the last year, the Total Liabilities & Equity growth was 27%. The average annual Total Liabilities & Equity growth rates for TriSalus Life Sciences Inc have been -53% over the past three years .
You don't have any saved screeners yet
